High Prevalence of Brain Tumor and R&D of New Drugs to Augment Growth of Anaplastic Astrocytoma Treatment Market
High prevalence of brain tumor is expected to propel growth of the anaplastic astrocytoma treatment market. For instance, according to The Central Brain Tumor Registry of the United States (2020 CBTRUS Statistical Report), the incidence rate of primary malignant and non-malignant brain and other central nervous system tumors in the U.S was 23.79 cases per 100,000 for an overall total count of 415,411 incident tumors. Moreover, R&D of new drugs is also expected to aid in growth of the market. For instance, in April 2020, Mateon Therapeutics Inc. announced the publication of a peer-reviewed research articlereporting the analysis of the long-term follow-up data on the recalcitrant/resistant anaplastic astrocytoma patient subpopulation treated in the NCT00431561 study, in the oncology journal Cancer Reports and Reviews. Similarly, in December 2020, KIYATEC, Inc. announced the initial clinical use of its response-prediction test to boost outcomes in relapsed brain cancer p...